Objectives: The diagnosis of primary Sjogren's syndrome (pSS) continues to be difficult and several patients keep symptomatic for years with different diagnoses before confirmation of pSS. Since the IL-23-IL-17 axis is involved in the etiopathogenesis of pSS we evaluated by immunohistochemistry and morphometric methods the presence of IL-17 as well as IL-23 within minor salivary glands (MSG) obtained from patients with uncertain diagnosis of pSS.

Materials And Methods: 42 patients, with symptoms attributable to pSS, and 8 patients used as a control, were enrolled for the study. Autoantibody detection, histological analysis for the presence of Germinal Centers (GC+), immunohistochemistry to detect IL-23 and IL-17 were performed.

Results: The detection of GC + anti-SSA and anti-SSB antibody in parallel with the detection of IL-17 and IL-23, displays only a diagnostic reinforcement value. Instead, the detection of a positive reaction for both IL-17 and IL-23 without GC + or autoantibody within minor salivary glands, as detected in 36 % of patients with uncertain diagnosis, may be hold as a sensitive and specific marker to identify those patients who are likely to evolve into pSS.

Conclusion: we suggest to use the IL-17/ IL-23 immunohistochemical detection to improve the identification of patients with a possible diagnosis in all cases which do not fully meet the American-European criteria for pSS, in particular when the GC + are not present at histopathological analysis and anti-SSA and anti-SSB antibody are undetectable in the serum.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2020.153137DOI Listing

Publication Analysis

Top Keywords

il-17 il-23
12
immunohistochemical detection
8
detection il-17
8
patients
8
identification patients
8
patients diagnosis
8
sjogren's syndrome
8
minor salivary
8
salivary glands
8
patients uncertain
8

Similar Publications

Interleukin (IL) inhibitors are increasingly used in the management of moderate-to-severe plaque psoriasis. However, their use in patients with a history of cancer is debated. We conducted a multicenter retrospective study across nine Italian Dermatology Units to assess the real-world effectiveness and safety of IL inhibitors (IL-23, IL-17, IL-12/23) in 136 oncological patients with moderate-to-severe plaque psoriasis.

View Article and Find Full Text PDF

Fast, Present and Future of the Concept of Spondyloarthritis.

Curr Rheumatol Rep

January 2025

Rheumatologisches Versorgungszentrum Steglitz, Ruhr Universität Bochum, Schloßstr.110, 12163, Berlin, Germany.

Purpose Of Review: Axial spondyloarthritis (axSpA) is a rather prevalent chronic inflammatory rheumatic disease that affects already relatively young patients. It has been known better since the end of the nineteenth century but quite a lot has been learned since the early 60ies when the first classification (diagnostic) criteria for ankylosing spondylitis (AS) were agreed on. I have been part of many developments in the last 30 years, and I'm happy to have been able to contribute to the scientific progress in terms of diagnosis, imaging, pathophysiology and therapy.

View Article and Find Full Text PDF

Background: Psoriasis patients who are seropositive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) face an elevated risk of hepatitis B virus reactivation (HBVr) when treated with cytokine inhibitors. This study aims to elucidate the risk in this population.

Methods: A retrospective chart review was conducted to assess the risk of HBVr in 73 psoriasis patients treated with cytokine inhibitors from 2013 to 2023.

View Article and Find Full Text PDF

Biologics and Small Molecules for Inflammatory Nail Disorders: A Narrative Review.

Indian Dermatol Online J

December 2024

Department of Dermatology, Weill Cornell Medicine, New York, NY, USA.

Background: Inflammatory dermatological conditions, including psoriasis, lichen planus, eczema, and alopecia areata, are frequently accompanied by nail findings and can have a significant impact on quality of life. Biologic and small-molecule medications have been approved over the past several decades in treating patients with these inflammatory nail disorders. They may be used in conjunction with longstanding mainstays of treatment (topical and intralesional corticosteroids, topical vitamin D3 analogs).

View Article and Find Full Text PDF

Association of increased serum I-309 with phenotypes, disease activity, and cytokine pattern in primary Sjögren's syndrome.

Clin Rheumatol

January 2025

Department of Laboratory Medicine, Huangyan Hospital of Wenzhou Medical University, Taizhou First People's Hospital, Taizhou, Zhejiang, China.

The aim of this study was to determine serum I-309 levels in primary Sjögren's syndrome (pSS) patients, as well as the association with disease phenotype, systemic activity, and T helper cell-related cytokines. A total of 58 pSS patients and 30 healthy controls (HC) were enrolled in this study. The concentrations of serum I-309, interleukin-4 (IL-4), IL-6, IL-9, IL-13, IL-17, IL-22, IL-23, tumor-necrosis factor-α (TNF-α), interferon-γ (IFN-γ), IFN-α, and IFN-β were measured with multiplex immunoassay.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!